FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a non-viral capsid-free DNA vector with covalently closed ends (ccDNA vector) for delivering nucleic acid, a ccDNA expression construct which codes ccDNA, a host cell for producing the ccDNA expression construct, method of producing a ccDNA vector, using a composition comprising a ccDNA vector for treating, preventing, relieving, monitoring or diagnosing a disease or disorder in a subject, a method of delivering a therapeutic protein to a subject, a kit for delivering a nucleic acid and a kit for producing a ccDNA vector. In one embodiment, the ccDNA vector comprises a nucleic acid sequence flanked by two symmetric ITRs which are not wild-type ITRs.
EFFECT: invention extends the range of means for delivering nucleic acid.
56 cl, 29 dwg, 7 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
MODIFIED CLOSED-ENDED DNA (scDNA) | 2018 |
|
RU2800026C2 |
MODULATION OF REP PROTEIN ACTIVITY WHEN PRODUCING CLOSED-END DNA (ceDNA) | 2020 |
|
RU2812850C2 |
GENE EDITING USING MODIFIED CLOSED-END DNA (ceDNA) | 2018 |
|
RU2811724C2 |
CLOSED-ENDED DNA VECTORS OBTAINED BY CELL-FREE SYNTHESIS, AND METHOD OF PRODUCING CEDNA VECTORS | 2019 |
|
RU2820586C2 |
NON-VIRAL DNA VECTORS AND OPTIONS FOR THEIR USE FOR EXPRESSION OF THERAPEUTIC AGENT BASED ON PHENYLALANINE HYDROXYLASE (PAH) | 2020 |
|
RU2814137C2 |
NON-VIRAL DNA VECTORS AND THEIR USE FOR THE PRODUCTION OF ANTIBODIES AND FUSION PROTEINS | 2019 |
|
RU2800914C2 |
NON-VIRAL DNA VECTORS AND OPTIONS FOR THEIR USE FOR EXPRESSION OF THERAPEUTIC AGENT BASED ON FACTOR VIII (FVIII) | 2020 |
|
RU2812852C2 |
CONTROLLED EXPRESSION OF TRANSGENES USING CLOSED-END DNA VECTORS (ceDNA) | 2019 |
|
RU2816871C2 |
MODULATING POLYNUCLEOTIDES | 2015 |
|
RU2749882C2 |
MODULATING POLYNUCLEOTIDES | 2015 |
|
RU2719192C2 |
Authors
Dates
2024-04-08—Published
2019-11-08—Filed